AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 23, 2024

The eye is exposed to the elements so it’s a window for bacteria and viruses to enter the body – potentially causing death. Ultra long, thick eyelashes might be in vogue but are they worth the expense – and the risk to health? Our natural eyelashes perform important functions. Eyelashes protect our eyes by diverting […]

Bacteria 246

Bacteria Clinical Trials Clinical Trials Trials 246

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 11, 2024

Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.

Vaccination 240

Vaccination Vaccine Bacteria Protein 240

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 23, 2024

But bacteria aren’t the only mutating pathogens we need to worry about. (Tanja Ivanova/Getty Images) The world is in the midst of an antibiotic resistance crisis that contributes to the death of nearly 5 million people a year.

Scientist 245

Scientist Bacteria Medicine Clinical Trials 245

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 26, 2023

Many tiny organisms including bacteria, fungi and viruses normally live on our bodies, and even inside us. These are called the microbiome. The large number of these organisms living in the gastrointestinal tract are collectively known as the gut microbiome.

Bacteria 246

Bacteria Clinical Trials Clinical Trials Clinical Research 246

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 2, 2022

Scientists have discovered DNA-damaging molecules made by gut bacteria that may help explain why people with inflammatory bowel disease (IBD) have higher rates of colorectal cancer than those without the condition.

DNA 245

DNA Bacteria Scientist Research 245

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 11, 2024

Researchers have identified an entirely new class of antibiotic that can kill bacteria that are resistant to most current drugs.

Bacterium 242

Bacterium Bacteria Drugs Research 242

AuroBlog - Aurous Healthcare Clinical Trials blog

JUNE 28, 2023

Golden staph are ubiquitous bacteria, living harmlessly on the skin or inside the nose of nearly one in three people worldwide. Yet they are duplicitous, too. In some situations, golden staph (Staphylococcus aureus) can become monsters, causing dangerous infections in the skin, blood, bones, or elsewhere.

Scientist 246

Scientist Bacteria Drugs Clinical Trials 246

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 9, 2022

Instead of the vaccine only protecting against the target bacteria – Myocbacterium tuberculosis – the tuberculosis vaccine offered broad protection against a range of unrelated infections, including respiratory infections and serious complications such as sepsis.

Vaccination 246

Vaccination Vaccine Bacteria Research 246

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 14, 2023

Called the gut microbiome, this dazzling collection of bacteria and other microorganisms has been the source of much attention – linked to a vast array of health conditions, from autism spectrum disorder and diabetes, to depression, […]

Bacteria 239

Bacteria Clinical Trials Clinical Trials Clinical Research 239

XTalks

JULY 31, 2020

A study published in Nature on July 30, 2020 states that good bacteria living in our gut can do much more than just help digest food and boost our immune system. According to studies conducted by researchers at Cincinnati Children’s Hospital, the bacteria can help heal damaged intestinal tissues.

Bacteria 98

Bacteria Genetic Engineering Engineer Research 98

Pharmaceutical Technology

AUGUST 17, 2022

The Phase III trial announcement comes at a notable time, as the number of Lyme disease cases is growing over the long term in several countries, including the UK and the US. Lyme disease is also known as borreliosis, which refers to the borrelia bacteria that cause the condition. In June 2022, Pfizer acquired 8.1% of Valneva.

Vaccination 299

Vaccination Vaccine Bacteria Protein 299

XTalks

NOVEMBER 12, 2024

Pneumonia is a lung infection that can be caused by viruses, bacteria or fungi and can result in millions of hospitalizations and deaths annually. For example, recent clinical trials and regulatory approvals for RSV vaccines are notable milestones that indicate advancements in preventing viral pneumonia in both children and elderly adults.

Bacteria 110

Bacteria Life Science Vaccination Vaccine 110

XTalks

NOVEMBER 7, 2024

Research suggests that certain bacteria, particularly those associated with Demodex mites (tiny mites that naturally live on human skin) like Bacillus oleronius , could contribute to rosacea in some individuals. Other studies suggest that Helicobacter pylori bacteria infections may also cause rosacea.

FDA Approval 105

FDA Approval Dermatology Bacteria Clinical Trials 105

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Development 105

Scienmag

MARCH 11, 2021

A new clinical study has shown that supplements of a lactic acid bacterium may have positive effects by increasing the diversity of intestinal bacteria in these infants. Extremely preterm infants can suffer from a life-threatening inflammation of the gut.

Bacteria 72

Bacteria Bacterium Research Clinical Trials 72

Pharmaceutical Technology

FEBRUARY 26, 2023

Finch Therapeutics’s Phase III PRISM4 trial for recurrent Clostridioides difficile infection (CDI) and MaaT Pharma’s Phase III trial in steroid-resistant acute graft-versus-host disease were both put on hold. While the French MaaT Pharma has submitted further information to the FDA, its trial remains on hold. with placebo.

Bacteria 278

Bacteria Trials Research Medicine 278

BioSpace

OCTOBER 19, 2020

In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.

Bacteria 74

Bacteria Trials Vaccine Vaccination 74

Pharmaceutical Technology

DECEMBER 14, 2022

Bacteria naturally develop resistance to antibiotics over time, through genetic mutation, horizontal gene transfer between bacteria, or because of selective pressure. Virus versus bacteria. Phages are viruses of bacteria. Secondly, the relationships between phages and bacteria are very specific.

Bacteria 130

Bacteria DNA Clinical Trials Clinical Trials 130

Medical Xpress

JANUARY 17, 2023

A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial. aureus colonization in trial participants without harming the gut microbiota, which includes bacteria that can benefit people.

Trials 80

Trials Allergies Bacteria Clinical Trials 80

Pharmaceutical Technology

MAY 25, 2023

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. percentage points (96% CI, −0.3

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

BioSpace

DECEMBER 6, 2021

Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.

Genetic Engineering 77

Genetic Engineering Bacteria Engineer Genetics 77

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 7, 2022

In cases where picking at your nose damages internal tissues, critical species of bacteria have a clearer path to the brain, which responds to their presence in ways that resemble signs of Alzheimer’s disease. […].

Bacteria 130

Bacteria Development Clinical Trials Clinical Trials 130

The Pharma Data

MARCH 18, 2022

Columbia Engineering researchers report that they have developed a “cloaking” system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells in mice. Using Bacteria For Therapy. Some trials had to be terminated due to severe toxicity.”

Bacteria 52

Bacteria Engineer Drugs Research 52

Pharmaceutical Technology

OCTOBER 6, 2022

Additionally, it will work on non-clinical toxicity (TOX) and Clinical Trial Material batch to conduct a Phase I clinical trial of the vaccine in healthy adult subjects. This trial will evaluate the safety of the vaccine and generate efficacy data. A sexually transmitted disease, gonorrhoea is caused by the NG bacteria.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

Medical Xpress

APRIL 17, 2023

A randomized clinical trial is looking at whether fecal microbiota transplantation (FMT) from healthy donors into adults with early-stage amyotrophic lateral sclerosis (ALS—one of the most common forms of motor neuron disease) can modulate the immune reaction during inflammation responses that characterize disease progression, and aims to investigate (..)

Bacteria 98

Bacteria Clinical Trials Clinical Trials Trials 98

Pharmaceutical Technology

MAY 18, 2023

The drug is GMP-manufactured by Lumen Bioscience in Seattle, US, and is intended to be given concomitantly with normal antibiotics and for eight weeks thereafter, offering protection from re-infection while commensal bacteria recolonise the gastrointestinal tract. Pivotal trials on LMN-201 are expected to commence in 2023.

Bacterium 130

Bacterium Bacteria FDA Approval Trials 130

Rethinking Clinical Trials

JUNE 6, 2023

The purpose of the trial is to reduce unnecessary broad-spectrum antibiotic use in non-intensive care unit inpatients. The 12-month trial is currently in month 5, and the team has already seen a downward inflection in broad-spectrum antibiotic use.

Trials 130

Trials Clinical Trials Clinical Trials Allergies 130

Pharmaceutical Technology

SEPTEMBER 22, 2022

A late-stage asset of Spero, tebipenem HBr is being developed as the first oral carbapenem antibiotic to treat cUTIs, including pyelonephritis, which are caused by specific bacteria. Spero will handle the execution and expenses linked to the Phase III trial of tebipenem HBr.

Bacteria 147

Bacteria Marketing Trials Clinical Development 147

Pharmaceutical Technology

APRIL 26, 2023

Vedanta Biosciences intends to use the funds to advance a pivotal Phase III trial of its lead candidate, VE303, to prevent recurrent clostridioides difficile infection (CDI). It comprises eight types of clonal human commensal bacteria strains chosen to offer colonisation resistance to C difficile.

Bacteria 130

Bacteria Life Science Trials Medicine 130

Scienmag

APRIL 19, 2021

Researchers from Aarhus University and Aarhus University Hospital replace sick intestinal bacteria with intestinal bacteria from healthy donors in a treatment intended to help patients with cirrhosis of the liver. The Novo Nordisk Foundation supports the Credit: Simon Mark Dahl Baumwall.

Bacteria 94

Bacteria Research Clinical Trials Clinical Trials 94

Delveinsight

JANUARY 28, 2021

Nirogy’s lead program aims lactate transporters for cancer treatment and is anticipated to enter human clinical trials in 2022. The NDA submission comprises data from the SURE-1, SURE-2 and SURE-3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no major drug-related adverse events.

Bacteria 52

Bacteria Trials Drugs Clinical Trials 52

XTalks

OCTOBER 29, 2024

Although UTIs are often straightforward to treat, they are commonly caused by strains of bacteria increasingly resistant to traditional antibiotics, such as amoxicillin and ciprofloxacin. Orlynvah was generally well tolerated in both SURE 1 and REASSURE clinical trials.

FDA Approval 105

FDA Approval Bacteria Clinical Trials Clinical Trials 105

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells. The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB).

Vaccination 100

Vaccination Vaccine Research Bacteria 100

Rethinking Clinical Trials

OCTOBER 3, 2024

Proctor Foundation University of California, San Francisco Slides Keywords Child Mortality; Antibiotics; Large Simple Trial Key Points Trachoma is a disease that affects the human eye, caused by infection with a strain of chlamydia.                       Speaker Thomas Lietman, MD Director Francis I.

Trials 100

Trials Bacteria Research Clinical Trials 100

pharmaphorum

NOVEMBER 4, 2020

Since then the story of Alzheimer’s research has been one of expensive failures as experimental drugs, mainly targeting the amyloid plaques found in the brains of people with the disease, failed to stop or slow cognitive decline in clinical trials.

Trials 74

Trials Drugs Bacteria Pharma Companies 74

Pharmaceutical Technology

JUNE 14, 2023

The therapy comprises liposomes engineered to capture the virulence factors, which are produced by a wide range of Gram-positive and Gram-negative bacteria. The company is currently evaluating CAL02 in a Phase II clinical trial, which is expected to enrol 276 SCABP patients globally.

Bacteria 130

Bacteria Engineer Clinical Trials Clinical Trials 130

XTalks

OCTOBER 29, 2024

Although UTIs are often straightforward to treat, they are commonly caused by strains of bacteria increasingly resistant to traditional antibiotics, such as amoxicillin and ciprofloxacin. Orlynvah was generally well tolerated in both SURE 1 and REASSURE clinical trials.

FDA Approval 98

FDA Approval Bacteria Clinical Trials Clinical Trials 98